Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors

被引：0
|
作者：
Junichi Yoshida
Kenichiro Shiraishi
Tetsuro Tamura
Kazuhiro Otani
Tetsuya Kikuchi
Akiko Mataga
Takako Ueno
Masao Tanaka
机构：
[1] Infection Control Committee,Department of Medicine and Biosystemic Science
[2] Shimonoseki City Hospital,undefined
[3] Kyushu University Faculty of Medicine,undefined
来源：
Journal of Pharmaceutical Health Care and Sciences | / 8卷
关键词：
SARS-CoV-2; Casirivimab; Imdevimab; Fever; Hypoxia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors
    Yoshida, Junichi
    Shiraishi, Kenichiro
    Tamura, Tetsuro
    Otani, Kazuhiro
    Kikuchi, Tetsuya
    Mataga, Akiko
    Ueno, Takako
    Tanaka, Masao
    JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2022, 8 (01)
  • [2] Casirivimab-imdevimab and sotrovimab induce a stronger SARS-CoV-2 neutralizing antibody response than remdesivir
    Yasuda, Yuto
    Mutsuo, Satoru
    Fujimoto, Kana
    Arasawa, Soichi
    Tashima, Noriyuki
    Iwashima, Daisuke
    Takahashi, Ken-ichi
    RESPIROLOGY, 2023, 28 : 186 - 186
  • [3] Casirivimab-imdevimab to Prevent SARS-CoV-2 Infections in Solid Organ Transplant Recipients
    Dimeglio, Chloe
    Del Bello, Arnaud
    Chapuy-Regaud, Sabine
    Esposito, Laure
    Danet, Chloe
    Couat, Chloe
    Izopet, Jacques
    Kamar, Nassim
    TRANSPLANTATION, 2022, 106 (05) : E275 - E276
  • [4] Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients
    Liu, Esther C.
    Lee, Jennifer H.
    Loo, Angela
    Mazur, Shawn
    Sultan, Sam
    Aull, Meredith
    Lee, Jun B.
    Muthukumar, Thangamani
    Hartono, Choli
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (11): : 2900 - 2902
  • [5] Casirivimab-imdevimab monoclonal antibody treatment for an immunocompromised patient with persistent SARS-CoV-2 infection: a case report
    Sam, Karun Saathveeg
    Khosla, Pooja
    Taneja, Vinus
    Dessai, Rishikesh
    COMMUNICATIONS MEDICINE, 2024, 4 (01):
  • [6] Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection
    Shopen, Noah
    Dekel, Michal
    Mizrahi, Michal
    Zandberg, Efrat
    Talmud, Daniel
    Cohen, Neta
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 100 : 137 - 139
  • [7] Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
    Bierle, Dennis M.
    Ganesh, Ravindra
    Razonable, Raymund R.
    JOURNAL OF CLINICAL VIROLOGY, 2021, 145
  • [8] Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies
    Hagihara, Masao
    Hayashi, Hiroyoshi
    Nakashima, Shiori
    Imai, Yui
    Nakano, Hirofumi
    Uchida, Tomoyuki
    Inoue, Morihiro
    Sakai-Tagawa, Yuko
    Ito, Mutsumi
    Yamayoshi, Seiya
    Iwatsuki-Horimoto, Kiyoko
    Suzuki, Yutaka
    Kawaoka, Yoshihiro
    INTERNAL MEDICINE, 2024, 63 (16) : 2283 - 2287
  • [9] Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan
    Kanako Terakawa
    Daisuke Katagiri
    Keiki Shimada
    Lubna Sato
    Hideki Takano
    CEN Case Reports, 2022, 11 : 328 - 332
  • [10] SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab
    Heller, Martin
    Henrici, Clara
    Buettner, Judith
    Leube, Sebastian
    Treske, Isabelle
    Pospischil, Petra
    Doll, Michael
    Schanz, Ilka
    Hallier, Agnes
    Herrmann, Eva
    Schmidt, Michael
    Sarrazin, Christoph
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 129 : 260 - 265
12345